|
Activity Number:
|
467
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Wednesday, August 1, 2007 : 2:00 PM to 3:50 PM
|
|
Sponsor:
|
Section on Bayesian Statistical Science
|
| Abstract - #309593 |
|
Title:
|
Incorporating Patient's Characteristics in Cancer Phase I Clinical Trials Using Escalation with Overdose Control
|
|
Author(s):
|
Mourad Tighiouart*+ and André Rogatko and Zhiheng Xu
|
|
Companies:
|
Emory University and Emory University and Emory University
|
|
Address:
|
1365-B Clifton Rd, Atlanta, GA, 30322,
|
|
Keywords:
|
EWOC ; MTD ; Cancer phase I clinical trials ; Bayesian design
|
|
Abstract:
|
We describe a design for cancer phase I clinical trials that takes into account patients heterogeneity thought to be related to treatment susceptibility. The goal is to estimate the maximum tolerated dose given a set of patient specific covariate values. The design is Bayesian adaptive based on escalation with overdose control paradigm (EWOC). In the case of a binary covariate, we will assess the performance of this method by comparing the following designs via extensive simulations: (1) Design using a covariate,(2) Design ignoring the covariate, and (3) Design using separate trials. A similar comparison is made for a continuous covariate. Since we do not know whether or not the MTD depends on a given patient characteristic in general, we investigate a procedure for determining the minimum sample size needed in order to decide whether or not to include the covariate during the trial.
|
